Company: PRTA
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0001559053-25-000009
Chunk: 153

Company: PROTHENA CORP PUBLIC LTD CO
Filing Date: 2025-02-27
Form: 10-K
Item: Item 8
Chunk 153
---
 a control related to the estimated degree of completion of the events specified in the specific clinical study or trial contract. For a sample of certain prepaid and accrued research and development costs, we agreed the amount, duration and any key terms to the underlying contract. We examined underlying documentation and third-party evidence from contract research organizations and compared them to the inputs used in developing the estimated degree of completion of the events specified in the specific clinical study or trial contract. In addition, we inquired of the individuals who are responsible for monitoring and tracking the status of the clinical trials to understand the degree of completion of the reported activities.

/s/ KPMG LLP

We have served as the Company’s auditor since 2012.

San Francisco, California

February 27, 2025 

76

Prothena Corporation plc and Subsidiaries

Consolidated Balance Sheets

(in thousands, except share and per share data)

December 31,20242023AssetsCurrent assets:Cash and cash equivalents$471,388 $618,830 Accounts receivable— 5,159 Prepaid expenses and other current assets14,024 13,941 Restricted cash, current— 1,352 Total current assets485,412 639,282 Non-current assets:Property and equipment, net3,081 3,836 Operating lease right-of-use assets10,708 12,162 Deferred tax assets43,239 33,893 Restricted cash, non-current860 860 Other non-current assets3,808 6,349 Total non-current assets61,696 57,100 Total assets$547,108 $696,382 Liabilities and Shareholders’ EquityCurrent liabilities:Accounts payable$7,770 $25,391 Accrued research and development13,428 14,724 Deferred revenue, current8,850 — Lease liability, current2,610 1,114 Other current liabilities15,843 15,662 Total current liabilities48,501 56,891 Non-current liabilities:Deferred revenue, non-current3,448 67,405 Lease liability, non-current8,233 10,721 Total non-current liabilities11,681 78,126 Total liabilities60,182 135,017 Commitments and contingencies (Note 6)Shareholders’ equity:Euro deferred shares, €22 nominal value:— — Authorized shares — 10,000 at December